



## Geron to Participate in Stifel 2022 Healthcare Conference

11/7/2022

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Stifel 2022 Healthcare Conference in New York City on Tuesday, November 15, 2022 at 10:55 a.m. ET.

A webcast of the presentation will be available through the Investor Relations section of Geron's website under **Events**. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

### About Geron

Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. Geron currently has two Phase 3 pivotal clinical trials underway evaluating imetelstat in lower risk myelodysplastic syndromes (LR MDS), and in relapsed/refractory myelofibrosis (MF). To learn more, visit [www.geron.com](http://www.geron.com) or follow us on [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221107005249/en/): <https://www.businesswire.com/news/home/20221107005249/en/>

Aron Feingold

Investor and Media Relations

[investor@geron.com](mailto:investor@geron.com)

[media@geron.com](mailto:media@geron.com)

Source: Geron Corporation